Paolo Morgese
Managing Director

Paolo Morgese is an healthcare investment and market access professional with more than 15 years experience in both assessing and supporting access of innovative healthcare technologies. In 2017, after having worked in the payer, the medical device, the pharma/biotech and in the healthcare investment industries, he founded forethought access – an early-stage market access consulting firm. Paolo’s interests and expertise are in healthcare technology value assessment and maximization; with particular interest in early stages of product development. Paolo is an engaged stakeholder in International, European and EU national policy debates around health technology assessment convergence, access to cell and gene therapies, early dialogue activities, value-based pricing/contracting and other market access related topics. He is the past chair of the European Biotech Industry Association HTA task force, biotech industry representative at the EUnetHTA Joint Action 2 Stakeholder Forum and current EU Director of Market Access and Member Relations at ARM, the Alliance for Regenerative Medicine.

Paolo Morgese holds a BSc in Economics from the University of Siena (Italy) and a MSc in Financial and Business Economics from the University of Essex (UK)


Brigitte Casteels Rappagliosi
Medical Device Consulting

Brigitte Casteels-Rappagliosi is an acknowledged international business leader who combines strong commercial acumen and extensive field experience in Market Access, Funding and Reimbursement, and Public Affairs for Medical Technology, including medical devices and in vitro diagnostics. Brigitte founded BC Consulting and Solutions in 2011 to deliver personalized, inclusive and international consulting services to the innovative medical technology companies that aim to invest and expand their footprint in Europe. Prior to that, Brigitte developed a long-standing career in the medical devices industry, including executive positions in major corporations as well as innovative SMEs.

Thanks to more than 20 years of professional activity, Brigitte engages with relevant public health authorities’ networks and decision makers across Europe, including the European institutions, on critical issues impacting the medical devices industry.

Brigitte has led successful reimbursement strategies introducing new medical devices in several western European markets such as: France, Belgium, Italy, Spain, UK, Netherlands, Germany, Austria, Switzerland and Italy.

Brigitte is a trained pharmacist by the University of Antwerpen – Belgium


Daniel Adam Blanco
Health Economist and Epidemiologist

Daniel is a health economist and epidemiologist by training with international experience in funding/reimbursement systems, scientific advice and modelling. Prior to joining BC Consulting and Solutions in September 2015, Daniel worked for the Andalusian HTA organization (AETSA) and several consulting companies in Sweden. He has several publications in the field of bariatric surgery, cardiovascular diseases and the evaluation of technologies. He also has expertise in reimbursement and funding pathways in Spain, France, Belgium, Italy and UK.

Daniel has an MSc in Economics by the Pablo de Olavide University, a Postgraduate Degree in Pharmacoeconomics by the Pompeu Fabra University and is completing an MSc in Epidemiology by the London School of Hygiene and Tropical Medicine.

Country partners


Sylvie Dole

Founder – Medaccess

Sylvie Dole has spent 17 years in the French affiliates of two Big Pharma, ROCHE and BMS, where she has held several positions in Market Access and Economic / Governmental affairs. She has been consultant since 2012 and in 2015 she founded Medaccess, a consultancy company specialized in Market Access Solutions for pharmaceuticals, biotechnologies and medical devices in France.

Her expertise is based over 20 years of Market Access experience at all stages of the lifecycle, from retail to hospital setting, for several drug status and therapeutic areas, through strategical and operational achievements covering various and complex market access situations.

Sylvie is also author and co-author of Health Economics publications and of a report on the HTA process of Medical Devices in France in 2014 (LES ECHOS ETUDES)

She has completed pre-doctoral studies in Public Health and Health Economics (Paris Sud University), holds a master degree in Applied Mathematics and Social Sciences (La Sorbonne University) and a university degree in Clinical Trial Practice (Pierre & Marie Curie University).


Thomas Ecker

CEO – Ecker & Ecker

Thomas Ecker is founder and CEO of Ecker + Ecker GmbH and based in Hamburg (Germany).

Thomas is a leading expert on market access in Germany for pharmaceuticals and medical devices with more than 20 years of experience in this sector. His special focus is on early benefit assessment. He regularly contributes to international conferences like iHEA, ISPOR and dggoe. He has worked on a broad range of indications, including ATMPs and orphan drugs.

He received his Master Economics and his PhD at Bayreuth University (Germany)


Gianluca Furneri

CEO – EBMA consulting

Gianluca Furneri is an independent pharmaceutical and device market access consultant. He is the CEO of Evidence Based Market Access (EBMA) and based in Milan (Italy).

Gianluca has strong expertise in Italian but also international strategic market access, pricing and reimbursement projects, and specializes in economic evaluations in healthcare. He co-authored publications on pharmacoeconomics and pharmaco-utilization and has lectured at several healthcare economics conferences. He has worked in many different therapeutic areas such as cardiovascular diseases, infectious diseases, neurology, metabolic diseases, oncology, neonatology and autoimmune diseases.

He received his Master in Pharmacoeconomics at the University of Milan, his PhD in Chemistry at Catania University.


Jorge Mestre-Ferrandiz

Independent consultant

Jorge Mestre-Ferrandiz has over 15 years’ experience consulting to the pharmaceutical industry and related non-profit organisations. Clients have included a number of global top 30 pharmaceutical companies plus organisations such as the Medical Research Council, Wellcome Trust, Academy of Medical Sciences and EFPIA.

He specialises in the pricing and reimbursement of medicines, the economics of the industry, the likely impact of changes in public policy on innovation, market access, the economics of antimicrobial resistance (AMR), and pharmaceutical product portfolios.

He now works as an independent economics consultant, having spent nearly 15 years at The Office of Health Economics, starting as an Industrial Economist and finishing as Director of Consulting, in December 2016. He graduated with a PhD in Economic Analysis from the University Autonoma of Barcelona in 2001.

Dr Mestre-Ferrandiz has published over 50 papers on health economics and is regularly invited to speak on related topics at academic and commercial international conferences.

He is a Visiting Fellow at OHE, an Honorary Visiting Lecturer at the Department of Economics, City University London, and Health Economics Professor at Instituto de Empresa (IE) Business School, Madrid.